Loading…
Invivyd, Inc. is projected to decline to $0.5014 by 2027, a -6% move from its current price of $0.535. IVVD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $0.5091 | $0.5346 | $0.5614 | -0.07% |
| Aug 5 | $0.4985 | $0.5342 | $0.5725 | -0.14% |
| Aug 6 | $0.4904 | $0.5338 | $0.5811 | -0.22% |
| Aug 7 | $0.4837 | $0.5335 | $0.5883 | -0.29% |
| Aug 8 | $0.4778 | $0.5331 | $0.5947 | -0.36% |
| Aug 9 | $0.4725 | $0.5327 | $0.6005 | -0.43% |
| Aug 10 | $0.4676 | $0.5323 | $0.6059 | -0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4676 | $0.5323 | $0.6059 | -0.51% |
| Week 2 | $0.441 | $0.5296 | $0.6361 | -1.01% |
| Week 3 | $0.421 | $0.5269 | $0.6594 | -1.51% |
| Week 4 | $0.4046 | $0.5243 | $0.6793 | -2.01% |
| Week 5 | $0.3904 | $0.5216 | $0.6968 | -2.50% |
| Week 6 | $0.3779 | $0.519 | $0.7127 | -3.00% |
| Week 7 | $0.3665 | $0.5163 | $0.7274 | -3.49% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Invivyd, Inc. is a healthcare company that engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children.
It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Invivyd, Inc. (IVVD) is currently priced at $0.535 with a market cap of $157.61M and a rank of 3916. The stock sits in the Healthcare space and shows a near-term forecast of mixed sentiment with a neutral stance in 2026, and bearish in 2030, followed by bullish momentum in the 2040 and 2050 horizon.
The forecast suggests near-term stability around the current price, with mid-term drift toward higher levels in later years.
In 2026 the avg price is $0.535 with min $0.535 and max $0.6378, yielding ROI 0 and a NEUTRAL sentiment. By 2027-2029 the avg prices are $0.502, $0.4145 with max values $0.7313, $0.672 and ROI turning negative (−6.2, −22.5). After a pause, 2032-2033 show a potential uptick with avg values around $0.6239 and $0.6268 and ROIs of 16.6 and 17.2, respectively.
The long-range outlook strengthens toward 2040 and 2050, with 2040 avg $0.8266 and max $1.74 (ROI 54.5, sentiment BULLISH), and 2050 avg $1.32 and max $3.03 (ROI 146.5, sentiment BULLISH). These figures illustrate a path from near-term caution to stronger long-run upside potential.
A major floor 54.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 81.3% above — a clean break opens room to run.
A major ceiling 232.7% above — clearing it would confirm fresh momentum.
Key IVVD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IVVD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5726 | Sell | $0.572 | Sell |
| MA 10 | $0.607 | Sell | $0.6145 | Sell |
| MA 20 | $0.71 | Sell | $0.6911 | Sell |
| MA 50 | $0.8775 | Sell | $0.8813 | Sell |
| MA 100 | $1.18 | Sell | $1.12 | Sell |
| MA 200 | $1.62 | Sell | $1.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 27.92 | Buy |
| Stoch RSI (14) | 19.05 | Buy |
| CCI (20) | -113.27 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -34.52 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.51 | Sell |
| Awesome (5,34) | -0.21 | Sell |
| Ultimate (7,14,28) | 23.55 | Buy |
| Momentum (10) | -0.21 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 0.54 | Sell |
| ADX (14) | 32.68 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 30, with SMA50 at $0.8775 and SMA200 at $1.62. Near-term support is at $0.535 and resistance at $0.97. The 30-day range runs from a low of $0.3874 to a high of $0.7388, reflecting a relatively tight trading band around the current level.
Annualized volatility is high at 90%, underscoring notable swing potential within the period.
These readings point to a cautious stance in the immediate horizon, with limited downside protection around the $0.535 mark while upside is capped by the $0.97 resistance in the short term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.535 | $0.535 | $0.6388 | 0% | Neutral | |
| $0.3712 | $0.5014 | $0.7303 | -6% | Neutral | |
| $0.3462 | $0.4943 | $0.7649 | -8% | Neutral | |
| $0.278 | $0.416 | $0.6743 | -22% | Bearish | |
| $0.2717 | $0.4241 | $0.7143 | -21% | Bearish | |
| $0.318 | $0.5162 | $0.8984 | -4% | Neutral | |
| $0.3709 | $0.6249 | $1.12 | +17% | Neutral | |
| $0.3587 | $0.6262 | $1.15 | +17% | Neutral | |
| $0.3091 | $0.5585 | $1.05 | +4% | Neutral | |
| $0.296 | $0.5531 | $1.06 | +3% | Neutral | |
| $0.3767 | $0.8268 | $1.74 | +55% | Bullish | |
| $0.594 | $1.32 | $3.04 | +147% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.535 | $0.535 | $0.6497 | +0.00% |
| September 2026 | $0.413 | $0.4999 | $0.6299 | -6.56% |
| October 2026 | $0.4086 | $0.5008 | $0.6429 | +0.18% |
| November 2026 | $0.4101 | $0.5078 | $0.6616 | +1.41% |
| December 2026 | $0.387 | $0.4838 | $0.6388 | -4.73% |
Click any year to see its month-by-month IVVD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IVVD could reach as high as $0.6388, with a base case around $0.535 and support toward $0.535 — roughly 0% from $0.535. Price action looks broadly range-bound.
Expect IVVD to range from $0.3712 to $0.7303 through 2027. The $0.5014 average target implies a -6% move from current prices. That is -6% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The IVVD price prediction for 2028 points to an average of $0.4943 (low $0.3462, high $0.7649) — a potential decline of -8% on today's $0.535. Price action looks broadly range-bound.
In 2029, IVVD is projected to trade between $0.278 and $0.6743, averaging $0.416 — a potential decline of -22% from today's $0.535. That is -16% versus the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
Invivyd, Inc.'s 2030 outlook centres on $0.4241, within a $0.2717 to $0.7143 range. That is up +2% on the projected 2029 average. That marks a -21% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2031, IVVD could reach as high as $0.8984, with a base case around $0.5162 and support toward $0.318 — roughly -4% from $0.535. A consolidation phase looks the most probable path here.
Expect IVVD to range from $0.3709 to $1.12 through 2032. The $0.6249 average target implies a +17% move from current prices. That is up +21% on the projected 2031 average. Price action looks broadly range-bound.
The IVVD price prediction for 2033 points to an average of $0.6262 (low $0.3587, high $1.15) — a potential gain of +17% on today's $0.535. A consolidation phase looks the most probable path here.
In 2034, IVVD is projected to trade between $0.3091 and $1.05, averaging $0.5585 — a potential gain of +4% from today's $0.535. That is -11% versus the projected 2033 average. Price action looks broadly range-bound.
Invivyd, Inc.'s 2035 outlook centres on $0.5531, within a $0.296 to $1.06 range. That is -1% versus the projected 2034 average. That marks a +3% change versus current levels. A consolidation phase looks the most probable path here.
By 2040, IVVD could reach as high as $1.74, with a base case around $0.8268 and support toward $0.3767 — roughly +55% from $0.535. Momentum favours further upside here.
Expect IVVD to range from $0.594 to $3.04 through 2050. The $1.32 average target implies a +147% move from current prices. That is up +60% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IVVD today (≈ 1,869.158879 IVVD) could be worth
$2,467.46
+$1,467.46 (+147%) by 2050 · US Dollar
Based on the average projected IVVD price of $1.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IVVDwould be worth at today's price.
$1,000 invested in IVVD on Jul 31, 2025 (≈ 1,440.922178 IVVD) would be worth
$770.89
-$229.11 (-22.9%) today · 0.77× · US Dollar
Based on a IVVD entry price of $0.694 vs. today's $0.535.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.611 | $875.61 | -12.4% |
| 1 month ago | $0.854 | $626.46 | -37.4% |
| 3 months ago | $1.52 | $351.97 | -64.8% |
| 6 months ago | $1.74 | $307.47 | -69.3% |
| 1 year ago | $0.694 | $770.89 | -22.9% |
| All time (5.0y) ago | $20.88 | $25.62 | -97.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IVVD forecast.
Our base-case forecast reaches $1.10 around 2050.
Implied market cap at $1.10: $324.07M
The multi-year forecast shows a mixed but increasingly constructive arc. In 2026 the avg price remains $0.535 with ROI 0 and NEUTRAL sentiment, indicating a flat near term. The years 2027 through 2030 carry negative ROIs (−6.2, −7.5, −22.5, and −20.6 respectively) and Bearish to Neutral tones, suggesting limited upside in the mid-term.
From 2032 onward, the outlook improves with 2032 avg $0.6239 and 2033 avg $0.6268, ROIs 16.6 and 17.2, sustaining a Neutral stance. The horizon shifts decisively by 2040, where avg rises to $0.8266, max to $1.74 and ROI to 54.5 with a Bullish sentiment. By 2050, the avg reaches $1.32, max $3.03, and ROI is 146.5 with a Bullish tilt.
These figures are projections and not guarantees. They illustrate potential paths for IVVD prices under different scenarios, highlighting near-term headwinds and substantial longer-term upside, while acknowledging inherent uncertainty in asset price forecasting.
Tap a question to reveal the answer.
The 2030 forecast shows min $0.2721, avg $0.4248, max $0.7155, ROI −20.6, sentiment BEARISH.
The forecast shows negative ROIs in several years (e.g., 2027 −6.2, 2028 −7.5, 2029 −22.5, 2030 −20.6), with upside potential in 2040 (ROI 54.5) and 2050 (ROI 146.5). These are estimates, not guarantees.
Yes. The 2032 max is $1.12 and the 2033 max is $1.15, with 2032 avg $0.6239 and 2033 avg $0.6268.
The 2040 forecast shows min $0.3765, avg $0.8266, max $1.74, ROI 54.5, sentiment BULLISH.
The 2050 forecast shows min $0.5934, avg $1.32, max $3.03, ROI 146.5, sentiment BULLISH.
Invivyd, Inc. Community Discussion
0Share your Invivyd, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.